{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T12:39:45Z","timestamp":1789389585276,"version":"build-2803163510"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1007\/bf03346763","type":"journal-article","created":{"date-parts":[[2014,3,28]],"date-time":"2014-03-28T22:17:56Z","timestamp":1396045076000},"page":"1121-1127","source":"Crossref","is-referenced-by-count":26,"title":["Use of parathyroid hormone in hypoparathyroidism"],"prefix":"10.1007","volume":"36","author":[{"given":"N. E.","family":"Cusano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. R.","family":"Rubin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Irani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"J.","family":"Sliney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. P.","family":"Bilezikian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,3,27]]},"reference":[{"key":"BF03346763_CR1","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1002\/jbmr.483","volume":"26","author":"JP Bilezikian","year":"2011","unstructured":"Bilezikian JP, Khan A, Potts JT Jr, et al. Hypoparathyroidism in the adult: epidemiology, diagnosis, pathophysiology, target-organ involvement, treatment, and challenges for future research. J Bone Miner Res 2011, 26: 2317\u201337.","journal-title":"J Bone Miner Res"},{"key":"BF03346763_CR2","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1007\/s12020-012-9618-y","volume":"41","author":"NE Cusano","year":"2012","unstructured":"Cusano NE, Rubin MR, Sliney J Jr, Bilezikian JP. Mini-review: new therapeutic options in hypoparathyroidism. Endocrine 2012, 41: 410\u20134.","journal-title":"Endocrine"},{"key":"BF03346763_CR3","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1056\/NEJMcp0803050","volume":"359","author":"D Shoback","year":"2008","unstructured":"Shoback D. Clinical practice. Hypoparathyroidism. N Engl J Med 2008, 359: 391\u2013403.","journal-title":"N Engl J Med"},{"key":"BF03346763_CR4","doi-asserted-by":"publisher","first-page":"4507","DOI":"10.1210\/jc.2012-1808","volume":"97","author":"DM Mitchell","year":"2012","unstructured":"Mitchell DM, Regan S, Cooley MR, et al. Long-term follow-up of patients with hypoparathyroidism. J Clin Endocrinol Metab 2012, 97: 4507\u201314.","journal-title":"J Clin Endocrinol Metab"},{"key":"BF03346763_CR5","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1056\/NEJM199610103351505","volume":"335","author":"SH Pearce","year":"1996","unstructured":"Pearce SH, Williamson C, Kifor O, et al. A familial syndrome of hypocalcemia with hypercalciuria due to mutations in the calciumsensing receptor. N Engl J Med 1996, 335: 1115\u201322.","journal-title":"N Engl J Med"},{"key":"BF03346763_CR6","first-page":"3792","volume":"84","author":"T Sunthornthepvarakul","year":"1999","unstructured":"Sunthornthepvarakul T, Churesigaew S, Ngowngarmratana S. A novel mutation of the signal peptide of the preproparathyroid hormone gene associated with autosomal recessive familial isolated hypoparathyroidism. J Clin Endocrinol Metab 1999, 84: 3792\u20136.","journal-title":"J Clin Endocrinol Metab"},{"key":"BF03346763_CR7","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1530\/eje.0.1460215","volume":"146","author":"W Arlt","year":"2002","unstructured":"Arlt W, Fremerey C, Callies F, et al. Well-being, mood and calcium homeostasis in patients with hypoparathyroidism receiving standard treatment with calcium and vitamin D. Eur J Endocrinol 2002, 146: 215\u201322.","journal-title":"Eur J Endocrinol"},{"key":"BF03346763_CR8","doi-asserted-by":"publisher","first-page":"2356","DOI":"10.1210\/jc.2013-1239","volume":"98","author":"NE Cusano","year":"2013","unstructured":"Cusano NE, Rubin MR, McMahon DJ, et al. The effect of PTH(1\u201384) on quality of life in hypoparathyroidism. J Clin Endocrinol Metab 2013, 98: 2356\u201361.","journal-title":"J Clin Endocrinol Metab"},{"key":"BF03346763_CR9","doi-asserted-by":"crossref","unstructured":"Sikjaer T, Rolighed L, Ortenblad N, et al. PTH (1\u201384) Substitution Therapy in Hypoparathyroidism: Effects on Muscle Cells, Muscle Function, Postural Stability and Quality of Life. In: Program of the 34th Annual Meeting of the American Society of Bone and Mineral Research. Minneapolis, MN SA0141: 2012.","DOI":"10.1016\/j.bone.2012.02.557"},{"key":"BF03346763_CR10","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1359\/jbmr.080803","volume":"23","author":"MR Rubin","year":"2008","unstructured":"Rubin MR, Dempster DW, Zhou H, et al. Dynamic and structural properties of the skeleton in hypoparathyroidism. J Bone Miner Res 2008, 23: 2018\u201324.","journal-title":"J Bone Miner Res"},{"key":"BF03346763_CR11","first-page":"1617","volume":"76","author":"S Abugassa","year":"1993","unstructured":"Abugassa S, Nordenstrom J, Eriksson S, Sjoden G. Bone mineral density in patients with chronic hypoparathyroidism. J Clin Endocrinol Metab 1993, 76: 1617\u201321.","journal-title":"J Clin Endocrinol Metab"},{"key":"BF03346763_CR12","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1097\/00000441-199508000-00003","volume":"310","author":"JS Touliatos","year":"1995","unstructured":"Touliatos JS, Sebes JI, Hinton A, et al. Hypoparathyroidism counteracts risk factors for osteoporosis. Am J Med Sci 1995, 310: 56\u201360.","journal-title":"Am J Med Sci"},{"key":"BF03346763_CR13","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.bone.2009.09.020","volume":"46","author":"MR Rubin","year":"2010","unstructured":"Rubin MR, Dempster DW, Kohler T, et al. Three dimensional cancellous bone structure in hypoparathyroidism. Bone 2010, 46: 190\u20135.","journal-title":"Bone"},{"key":"BF03346763_CR14","doi-asserted-by":"publisher","first-page":"2727","DOI":"10.1002\/jbmr.452","volume":"26","author":"MR Rubin","year":"2011","unstructured":"Rubin MR, Dempster DW, Sliney J Jr, et al. PTH(1\u201384) administration reverses abnormal bone-remodeling dynamics and structure in hypoparathyroidism. J Bone Miner Res 2011, 26: 2727\u201336.","journal-title":"J Bone Miner Res"},{"key":"BF03346763_CR15","doi-asserted-by":"publisher","first-page":"2358","DOI":"10.1002\/jbmr.470","volume":"26","author":"T Sikjaer","year":"2011","unstructured":"Sikjaer T, Rejnmark L, Rolighed L, et al. The effect of adding PTH(1\u201384) to conventional treatment of hypoparathyroidism: a randomized, placebo-controlled study. J Bone Miner Res 2011, 26: 2358\u201370.","journal-title":"J Bone Miner Res"},{"key":"BF03346763_CR16","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1172\/JCI100224","volume":"7","author":"F Albright","year":"1929","unstructured":"Albright F, Ellsworth R. Studies on the physiology of the parathyroid glands: I. Calcium and Phosphorus Studies on a Case of Idiopathic Hypoparathyroidism. J Clin Invest 1929, 7: 183\u2013201.","journal-title":"J Clin Invest"},{"key":"BF03346763_CR17","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s12020-011-9570-2","volume":"41","author":"G Mazziotti","year":"2012","unstructured":"Mazziotti G, Bilezikian J, Canalis E, et al. New understanding and treatments for osteoporosis. Endocrine 2012, 41: 58\u201369.","journal-title":"Endocrine"},{"key":"BF03346763_CR18","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1001\/jama.1996.03540080053029","volume":"276","author":"KK Winer","year":"1996","unstructured":"Winer KK, Yanovski JA, Cutler GB Jr. Synthetic human parathyroid hormone 1\u201334 vs calcitriol and calcium in the treatment of hypoparathyroidism. JAMA 1996, 276: 631\u20136.","journal-title":"JAMA"},{"key":"BF03346763_CR19","first-page":"3480","volume":"83","author":"KK Winer","year":"1998","unstructured":"Winer KK, Yanovski JA, Sarani B, Cutler GB Jr. A randomized, crossover trial of once-daily versus twice-daily parathyroid hormone 1\u201334 in treatment of hypoparathyroidism. J Clin Endocrinol Metab 1998, 83: 3480\u20136.","journal-title":"J Clin Endocrinol Metab"},{"key":"BF03346763_CR20","doi-asserted-by":"publisher","first-page":"4214","DOI":"10.1210\/jc.2002-021736","volume":"88","author":"KK Winer","year":"2003","unstructured":"Winer KK, Ko CW, Reynolds JC, et al. Long-term treatment of hypoparathyroidism: a randomized controlled study comparing parathyroid hormone-(1\u201334) versus calcitriol and calcium. J Clin Endocrinol Metab 2003, 88: 4214\u201320.","journal-title":"J Clin Endocrinol Metab"},{"key":"BF03346763_CR21","doi-asserted-by":"publisher","first-page":"3389","DOI":"10.1210\/jc.2007-2552","volume":"93","author":"KK Winer","year":"2008","unstructured":"Winer KK, Sinaii N, Peterson D, et al. Effects of once versus twice-daily parathyroid hormone 1\u201334 therapy in children with hypoparathyroidism. J Clin Endocrinol Metab 2008, 93: 3389\u201395.","journal-title":"J Clin Endocrinol Metab"},{"key":"BF03346763_CR22","doi-asserted-by":"publisher","first-page":"2680","DOI":"10.1210\/jc.2009-2464","volume":"95","author":"KK Winer","year":"2010","unstructured":"Winer KK, Sinaii N, Reynolds J et al. Long-term treatment of 12 children with chronic hypoparathyroidism: a randomized trial comparing synthetic human parathyroid hormone 1\u201334 versus calcitriol and calcium. J Clin Endocrinol Metab 2010, 95: 2680\u20138.","journal-title":"J Clin Endocrinol Metab"},{"key":"BF03346763_CR23","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1210\/jc.2011-1908","volume":"97","author":"KK Winer","year":"2011","unstructured":"Winer KK, Zhang B, Shrader JA, et al. Synthetic human parathyroid hormone 1\u201334 replacement therapy: a randomized crossover trial comparing pump versus injections in the treatment of chronic hypoparathyroidism. J Clin Endocrinol Metab 2011, 97: 391\u20139.","journal-title":"J Clin Endocrinol Metab"},{"key":"BF03346763_CR24","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1002\/jbmr.1627","volume":"27","author":"RI Gafni","year":"2012","unstructured":"Gafni RI, Brahim JS, Andreopoulou P, et al. Daily parathyroid hormone 1\u201334 replacement therapy for hypoparathyroidism induces marked changes in bone turnover and structure. J Bone Miner Res 2012, 27: 1811\u201320.","journal-title":"J Bone Miner Res"},{"key":"BF03346763_CR25","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1007\/s00198-009-1149-x","volume":"21","author":"MR Rubin","year":"2010","unstructured":"Rubin MR, Sliney J Jr, McMahon DJ, et al. Therapy of hypoparathyroidism with intact parathyroid hormone. Osteoporos Int 2010, 21: 1927\u201334.","journal-title":"Osteoporos Int"},{"key":"BF03346763_CR26","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1002\/jbmr.1493","volume":"27","author":"T Sikjaer","year":"2012","unstructured":"Sikjaer T, Rejnmark L, Thomsen JS, et al. Changes in 3-dimensional bone structure indices in hypoparathyroid patients treated with PTH(1\u201384): a randomized controlled study. J Bone Miner Res 2012, 27: 781\u20138.","journal-title":"J Bone Miner Res"},{"key":"BF03346763_CR27","unstructured":"Shoback D, Clarke B, Brandi ML, et al. Safety and tolerability of recombinant human parathyroid hormone (rhPTH[1\u201384]) in a randomized, double-blind, placebo-controlled study for the treatment of adults with hypoparathyroidism. In: The Endocrine Society\u2019s 94th Annual Meeting and Expo. Houston, TX SUN-325: 2012."},{"key":"BF03346763_CR28","unstructured":"Bilezikian JP, Clarke B, Mannstadt M, et al. Effect of recombinant human parathyroid hormone (rhPTH[1\u201384]) on skeletal dynamics and BMD in hypoparathyroidism: the REPLACE study. In: Program of the 34th Annual Meeting of the American Society of Bone and Mineral Research. Minneapolis, MN MO0132: 2012."},{"key":"BF03346763_CR29","doi-asserted-by":"crossref","unstructured":"Hattersley G, Bilezikian J, Guerriero J, et al. Bone anabolic efficacy and safety of BA058, a novel analog of hPTHrP: results from a phase 2 clinical trial in postmenopausal women with osteoporosis. In: The Endocrine Society\u2019s 94th Annual Meeting and Expo. Houston, TXOR08-1: 2012.","DOI":"10.1530\/boneabs.01.OC5.5"},{"key":"BF03346763_CR30","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1210\/jc.2012-2984","volume":"98","author":"NE Cusano","year":"2013","unstructured":"Cusano NE, Rubin MR, McMahon DJ, et al. Therapy of hypoparathyroidism with PTH(1\u201384): a prospective four-year investigation of efficacy and safety. J Clin Endocrinol Metab 2013, 98: 137\u201344.","journal-title":"J Clin Endocrinol Metab"},{"key":"BF03346763_CR31","first-page":"1535","volume":"77","author":"R Lindsay","year":"1993","unstructured":"Lindsay R, Nieves J, Henneman E, et al. Subcutaneous administration of the amino-terminal fragment of human parathyroid hormone-(1\u201334): kinetics and biochemical response in estrogenized osteoporotic patients. J Clin Endocrinol Metab 1993, 77: 1535\u20139.","journal-title":"J Clin Endocrinol Metab"},{"key":"BF03346763_CR32","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/S0009-9236(97)90169-7","volume":"61","author":"HR Schwietert","year":"1997","unstructured":"Schwietert HR, Groen EW, Sollie FA, Jonkman JH. Single-dose subcutaneous administration of recombinant human parathyroid hormone [rhPTH(1\u201384)] in healthy postmenopausal volunteers. Clin Pharmacol Ther 1997, 61: 360\u201376.","journal-title":"Clin Pharmacol Ther"},{"key":"BF03346763_CR33","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1590\/S0004-27302010000200019","volume":"54","author":"MR Rubin","year":"2010","unstructured":"Rubin MR, Bilezikian JP. Hypoparathyroidism: clinical features, skeletal microstructure and parathyroid hormone replacement. Arq Bras Endocrinol Metabol 2010, 54: 220\u20136.","journal-title":"Arq Bras Endocrinol Metabol"},{"key":"BF03346763_CR34","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1080\/01926230252929882","volume":"30","author":"JL Vahle","year":"2002","unstructured":"Vahle JL, Sato M, Long GG, et al. Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1\u201334) for 2 years and relevance to human safety. Toxicol Pathol 2002, 30: 312\u201321.","journal-title":"Toxicol Pathol"},{"key":"BF03346763_CR35","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1080\/01926230601072301","volume":"34","author":"J Jolette","year":"2006","unstructured":"Jolette J, Wilker CE, Smith SY, et al. Defining a noncarcinogenic dose of recombinant human parathyroid hormone 1\u201384 in a 2-year study in Fischer 344 rats. Toxicol Pathol 2006, 34: 929\u201340.","journal-title":"Toxicol Pathol"},{"key":"BF03346763_CR36","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.1002\/jbmr.1768","volume":"27","author":"EB Andrews","year":"2012","unstructured":"Andrews EB, Gilsenan AW, Midkiff K, et al. The US postmarketing surveillance study of adult osteosarcoma and teriparatide: Study design and findings from the first 7 years. J Bone Miner Res 2012, 27: 2429\u201337.","journal-title":"J Bone Miner Res"},{"key":"BF03346763_CR37","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1002\/jbmr.1800","volume":"27","author":"C Cipriani","year":"2012","unstructured":"Cipriani C, Irani D, Bilezikian JP. Safety of osteoanabolic therapy: a decade of experience. J Bone Miner Res 2012, 27: 2419\u201328.","journal-title":"J Bone Miner Res"},{"key":"BF03346763_CR38","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1055\/s-0032-1308971","volume":"44","author":"G Diaz-Soto","year":"2012","unstructured":"Diaz-Soto G, Mora-Porta M, Nicolau J, et al. Efficacy and safety of long term treatment of unresponsive hypoparathyroidism using multipulse subcutaneous infusion of teriparatide. Horm Metab Res 2012, 44: 708\u201310.","journal-title":"Horm Metab Res"},{"key":"BF03346763_CR39","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1359\/jbmr.081233","volume":"24","author":"TA Theman","year":"2009","unstructured":"Theman TA, Collins MT, Dempster DW, et al. PTH(1\u201334) replacement therapy in a child with hypoparathyroidism caused by a sporadic calcium receptor mutation. J Bone Miner Res 2009, 24: 964\u201373.","journal-title":"J Bone Miner Res"},{"key":"BF03346763_CR40","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s11095-010-0192-9","volume":"28","author":"PE Daddona","year":"2011","unstructured":"Daddona PE, Matriano JA, Mandema J, Maa YF. Parathyroid hormone (1\u201334)-coated microneedle patch system: clinical pharmacokinetics and pharmacodynamics for treatment of osteoporosis. Pharm Res 2011, 28: 159\u201365.","journal-title":"Pharm Res"},{"key":"BF03346763_CR41","doi-asserted-by":"crossref","unstructured":"Hattersley G, Bilezikian JP, Guerriero J et al. Bone anabolic efficacy and safety of BA058, a novel analog of hPTHrP: results from a phase 2 clinical trial in postmenopausal women with osteoporosis. In: The Endocrine Society\u2019s 94th Annual Meeting and Expo. Houston, TX OR08-1: 2012","DOI":"10.1530\/boneabs.01.OC5.5"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03346763.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF03346763\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03346763","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03346763.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,18]],"date-time":"2020-02-18T02:27:24Z","timestamp":1581992844000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF03346763"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12]]},"references-count":41,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["BF03346763"],"URL":"https:\/\/doi.org\/10.1007\/bf03346763","relation":{},"ISSN":["0391-4097","1720-8386"],"issn-type":[{"value":"0391-4097","type":"print"},{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,12]]}}}